ArticleNature immunology2020
Interleukin-33 activates regulatory T cells to suppress innate γδ T cell responses in the lung.
Open access · greenAbstract read
In one paragraph
Article in Nature immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.
0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed
5.1field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 101 citations in OpenAlex.
- FM-GPT: Bayesian fine mapping for phenome-wide transcriptome-wide association studies.PLoS genetics · 2026Article
- Regulatory T cells sabotage anti-tumor γδ T cells by creating IL-2-deficient environments.The Journal of experimental medicine · 2026Article
- IL-2 mutein promotes antigen-specific transplant acceptance in mice through expansion of ST2Nature communications · 2026Article
- Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression.Cancer cell · 2026Article
- CCR6 is essential for effective immunity againstInfection and immunity · 2026Article
- FM-GPT: Bayesian fine mapping for phenome-wide transcriptome-wide association studies.bioRxiv : the preprint server for biology · 2026Article
- CCR8The Journal of allergy and clinical immunology · 2026Article
- Type 2 lymphocytes restrict type 3 lymphocytes during liver fibrosis and colocalize in fibroblast niches.Science advances · 2026Article
- Article
- A stage-based framework to interpret regulatory T cell biology after heart transplantation.Frontiers in cardiovascular medicine · 2026Review
- The emerging role of T cells in depression.Frontiers in psychiatry · 2026Review
- Beyond inhaled medications: precision medicine and biologic therapies targeting the IL-33/TSLP/type 2 axis in COPD.Frontiers in immunology · 2026Review
- IL-33 blockade in asthma: a story of hype, hope and hindsight.ERJ open research · 2026Article
- Multifaceted mechanisms of unconventional T cells in ischemia-reperfusion injury.Frontiers in immunology · 2026Review
- γδ T cells: bridging innate and adaptive immunity in development, tissue residency, and disease.Frontiers in immunology · 2026Review
- IL-27 promotes Treg cell expression of CD122 and fitness at homeostasis.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- The immunology of asthma and chronic rhinosinusitis.Nature reviews. Immunology · 2025Review
- Lymph node macrophages drive immune tolerance and resistance to cancer therapy by induction of the immune-regulatory cytokine IL-33.Cancer cell · 2025Article
- CXCL12+ fibroblastic reticular cells in lymph nodes facilitate immune tolerance by regulating T cell-mediated alloimmunity.The Journal of clinical investigation · 2025Article
- Dural Tregs driven by astrocytic IL-33 mitigate depression through the EGFR signals in mPFC neurons.Cell death and differentiation · 2025Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
10 authors at 2 institutions in 1 country.
Lucas D FaustinoCenter for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9535-3735
Jason W GriffithCenter for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Rod A RahimiCenter for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7929-2899
Keshav NepalCenter for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Daniel L HamilosCenter for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Josalyn L ChoCenter for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Benjamin D MedoffCenter for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
James J MoonCenter for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-8246-931X
Dario A A VignaliDepartment of Immunology, University of Pittsburgh School of Medicine and Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0002-2771-5992
Andrew D LusterCenter for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. aluster@mgh.harvard.edu.ORCID http://orcid.org/0000-0001-9679-7912
Harvard University · USUPMC Hillman Cancer Center · US
Funding
Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG · 1991 to 2026
$35.3MTetramer CoreU19AI095261 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI VON ANDRIAN, ULRICH H · 2011 to 2015
$10.8MResearch Training in Pulmonary Immunology and Allergy at MGHT32HL116275 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI David C Christiani, ANDREW D LUSTER · 2013 to 2026
$8.6MLung-Resident Memory Th2 cells in Asthma - New Therapeutic TargetsR01AI040618 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LUSTER, ANDREW D · 1997 to 2022
$5.6MChemokines and Th2 Cell Trafficking in AsthmaR37AI040618 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LUSTER, ANDREW D · 2008 to 2017
$4.0MInterleukin-35 and the tumor microenvironmentR01CA203689 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI VIGNALI, DARIO AA · 2016 to 2020
$1.9MDistinct Function and Control of Regulatory T Cell Subsets During InfluenzaK08AI125816 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI GRIFFITH, JASON W. · 2017 to 2021
$1.1MThe Role of Lung-Resident Memory Th2 cells in AsthmaK08HL140173 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI RAHIMI, ROD AMIR · 2018 to 2022
$866kNCI NIH HHS R01 CA203689NHLBI NIH HHS K08 HL140173NHLBI NIH HHS T32 HL116275NIAID NIH HHS K08 AI125816NIAID NIH HHS R01 AI040618NIAID NIH HHS R37 AI040618NIAID NIH HHS U19 AI095261NIDDK NIH HHS P30 DK043351
Abstract
Foxp3
Indexed as
ImmunomodulationAllergensAnimalsBiomarkersImmunophenotypingInterleukin-1 Receptor-Like 1 ProteinInterleukin-33Intraepithelial LymphocytesLeukocytesLungMiceT-Lymphocytes, RegulatoryAllergensBiomarkersIl1rl1 protein, mouseInterleukin-1 Receptor-Like 1 ProteinInterleukin-33
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.